Figure 3.

Grade change for adverse events from first-line atezolizumab plus bevacizumab treatment to second-line lenvatinib treatment. Atez/BV: atezolizumab plus bevacizumab used as the first-line treatment. 2nd LEN: atezolizumab plus bevacizumab used as first-line treatment, and lenvatinib used as second-line treatment. In patients with hypothyroidism or elevated AST/ALT levels during the second-line treatment, there was a change in the grade of adverse events from the first-line treatment to the second-line treatment. Numbers in brackets indicate the number of patients. Atez/BV, atezolizumab/bevacizumab; LEN, lenvatinib; AST/ALT, aspartate aminotransferase/alanine aminotransferase.